|
AU2006201274A1
|
|
Immunotherapy
|
|
WO2005073250A2
|
|
Medical treatment using an rna1 targeting a human notch signalling pathway member
|
|
GB0419703D0
|
|
Medical treatment
|
|
WO2005012349A2
|
|
Chromatographic process for the purification of notch ligands
|
|
GB0415318D0
|
|
Medical treatment
|
|
WO2004083372A2
|
|
Modulators of the notch signaling pathway immobilized on particles for modifying immune responses
|
|
GB0405405D0
|
|
Assays and medical treatments
|
|
GB0402562D0
|
|
Process
|
|
GB0402208D0
|
|
Process
|
|
GB0401792D0
|
|
Medical treatment
|
|
GB0401807D0
|
|
Medical treatment
|
|
WO2004064863A1
|
|
Treatment of autoimmune diseases using an activator for the notch signaling pathway
|
|
EP1585543A1
|
|
Treatment of autoimmune diseases using an activator for the notch signaling pathway
|
|
GB0401131D0
|
|
Modulators
|
|
GB0401130D0
|
|
Modulators
|
|
WO2004060262A2
|
|
Modulators of notch signalling for use in immunotherpapy
|
|
AU2003269268A1
|
|
Modulation of immune function
|
|
GB0323233D0
|
|
Medical treatment
|
|
GB0323130D0
|
|
Medical treatment
|
|
US7351413B2
|
|
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
